Delving into the Latest Updates on Neurotech USA, Inc. with Synapse

Overview

Ciliary neurotrophic factor (CNTF) is one of the most studied neurotrophic factors for neuroprotection of the retina. A large body of evidence demonstrates that CNTF promotes rod photoreceptor survival in almost all animal models. Recent studies indicate that CNTF also promotes cone photoreceptor survival and cone outer segment regeneration in the degenerating retina and improves cone function in dogs with congenital achromotopsia. In addition, CNTF is a neuroprotective factor and an axogenesis factor for retinal ganglion cells (RGCs). This review focuses on the effects of exogenous CNTF on photoreceptors and RGCs in the mammalian retina and the potential clinical application of CNTF for retinal degenerative diseases.

01 Jan 2012·Retinal Degenerative DiseasesQ4 · MEDICINE

Regeneration of Cone Outer Segments Induced by CNTF

Q4 · MEDICINE

Article

Author: Lingyu Luo ; Weng Tao ; Matthew M. LaVail ; Konrad Kauper ; Deqiang Huang ; Paul Stabila ; Yiwen Li ; Alan M. Laties ; Rong Wen

Hereditary retinal degenerations such as retinitis pigmentosa are a major cause of blindness.Although most mutations responsible for retinitis pigmentosa only affect rod photoreceptors directly, cones undergo a secondary degeneration.This study investigated secondary cone degeneration in the S334ter-3 rats treated with recombinant human CNTF protein.Results showed that CNTF promotes cone outer segment (COS) regeneration and reverses secondary cone degeneration.Sustained delivery of CNTF helped cones maintain COS and their functions.

01 Jul 2006·Expert Opinion on Biological TherapyQ3 · MEDICINE

Application of encapsulated cell technology for retinal degenerative diseases

Q3 · MEDICINE

Review

Author: Tao, Weng

Ophthalmic disorders represent a rapidly growing disease area that is associated with the ageing population. Their sight is threatened by age-related macular degeneration, diabetic retinopathy, glaucoma and/or retinitis pigmentosa (RP). Few effective treatments for these disorders are available at present, in part due to lack of effective delivery of therapeutic molecules to the retina. Encapsulated cell technology (ECT) allows the controlled, continuous and long-term administration of protein drugs in the eye, where therapeutic agents are needed, and does not subject the host to the systemic exposure. Furthermore, the implants can be retrieved, providing an added level of safety. Ciliary neurotrophic factor (CNTF) has been shown to protect the retina from degeneration in 13 animal models, and ECT-based delivery of CNTF protected photoreceptors in the rcd1 dog model of RP.

100 Deals associated with Neurotech USA, Inc.

Login to view more data

100 Translational Medicine associated with Neurotech USA, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data